Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Nevus, Pigmented | 16 | 2024 | 222 | 6.670 |
Why?
|
Skin Neoplasms | 48 | 2024 | 5837 | 6.300 |
Why?
|
Melanoma | 33 | 2024 | 5696 | 4.530 |
Why?
|
Nevus, Epithelioid and Spindle Cell | 7 | 2024 | 67 | 4.320 |
Why?
|
Melanosis | 4 | 2023 | 93 | 2.210 |
Why?
|
Dermatology | 12 | 2023 | 905 | 2.050 |
Why?
|
Dermoscopy | 3 | 2024 | 73 | 1.650 |
Why?
|
Pigmentation Disorders | 2 | 2022 | 105 | 1.510 |
Why?
|
Basal Cell Nevus Syndrome | 2 | 2022 | 38 | 1.460 |
Why?
|
Skin | 12 | 2023 | 4479 | 1.350 |
Why?
|
Hair Diseases | 2 | 2022 | 73 | 1.100 |
Why?
|
Granuloma | 3 | 2023 | 329 | 0.960 |
Why?
|
Nail Diseases | 2 | 2024 | 54 | 0.910 |
Why?
|
Epidermolysis Bullosa | 1 | 2024 | 29 | 0.900 |
Why?
|
Nevus, Blue | 1 | 2023 | 43 | 0.870 |
Why?
|
Neurocutaneous Syndromes | 2 | 2023 | 53 | 0.860 |
Why?
|
Sentinel Lymph Node Biopsy | 6 | 2023 | 729 | 0.850 |
Why?
|
Scalp Dermatoses | 1 | 2022 | 44 | 0.790 |
Why?
|
DNA, Neoplasm | 2 | 2020 | 1740 | 0.790 |
Why?
|
Callosities | 1 | 2021 | 5 | 0.790 |
Why?
|
Skin Diseases | 5 | 2024 | 1082 | 0.760 |
Why?
|
Sunburn | 2 | 2019 | 156 | 0.760 |
Why?
|
Child | 43 | 2024 | 80509 | 0.750 |
Why?
|
Skin Diseases, Viral | 1 | 2021 | 26 | 0.750 |
Why?
|
Nevus of Ota | 1 | 2021 | 3 | 0.740 |
Why?
|
Granuloma, Pyogenic | 1 | 2021 | 47 | 0.730 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2024 | 455 | 0.730 |
Why?
|
Skin Abnormalities | 1 | 2021 | 60 | 0.730 |
Why?
|
Pseudoxanthoma Elasticum | 1 | 2020 | 12 | 0.730 |
Why?
|
Penicillamine | 1 | 2020 | 59 | 0.720 |
Why?
|
Hepatolenticular Degeneration | 1 | 2020 | 73 | 0.700 |
Why?
|
Carcinoma, Basal Cell | 3 | 2020 | 565 | 0.700 |
Why?
|
Nevus | 1 | 2022 | 204 | 0.690 |
Why?
|
Cumulative Trauma Disorders | 1 | 2021 | 152 | 0.680 |
Why?
|
Fingers | 1 | 2021 | 509 | 0.610 |
Why?
|
Aluminum Compounds | 1 | 2018 | 56 | 0.590 |
Why?
|
Acne Vulgaris | 1 | 2022 | 352 | 0.560 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2022 | 4350 | 0.550 |
Why?
|
Hypersensitivity, Delayed | 1 | 2018 | 490 | 0.540 |
Why?
|
Urticaria | 1 | 2018 | 151 | 0.530 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2021 | 622 | 0.510 |
Why?
|
Cleft Lip | 1 | 2021 | 512 | 0.510 |
Why?
|
Drug Eruptions | 3 | 2014 | 334 | 0.500 |
Why?
|
Cleft Palate | 1 | 2021 | 592 | 0.500 |
Why?
|
Sweat Gland Diseases | 1 | 2015 | 12 | 0.490 |
Why?
|
Chlorides | 1 | 2018 | 666 | 0.470 |
Why?
|
Eccrine Glands | 1 | 2015 | 52 | 0.470 |
Why?
|
Child, Preschool | 21 | 2024 | 42478 | 0.470 |
Why?
|
Urinary Bladder | 5 | 2008 | 1155 | 0.460 |
Why?
|
Tumor Suppressor Proteins | 1 | 2024 | 2794 | 0.450 |
Why?
|
Infant | 18 | 2024 | 36375 | 0.450 |
Why?
|
Dermatitis, Atopic | 4 | 2024 | 728 | 0.450 |
Why?
|
Humans | 88 | 2024 | 765823 | 0.450 |
Why?
|
Adolescent | 27 | 2024 | 88794 | 0.450 |
Why?
|
Abnormalities, Multiple | 1 | 2021 | 1424 | 0.440 |
Why?
|
Biopsy | 7 | 2021 | 6765 | 0.420 |
Why?
|
Leg Injuries | 1 | 2015 | 180 | 0.420 |
Why?
|
Hamartoma | 1 | 2015 | 235 | 0.410 |
Why?
|
Diagnosis, Differential | 8 | 2024 | 12966 | 0.400 |
Why?
|
Central Nervous System Neoplasms | 1 | 2021 | 918 | 0.400 |
Why?
|
Giant Cells | 1 | 2013 | 187 | 0.400 |
Why?
|
Telemedicine | 4 | 2022 | 3106 | 0.390 |
Why?
|
Language | 1 | 2021 | 1550 | 0.380 |
Why?
|
Anti-Inflammatory Agents | 2 | 2012 | 1804 | 0.380 |
Why?
|
Clobetasol | 2 | 2014 | 33 | 0.380 |
Why?
|
Cyclin D1 | 1 | 2013 | 449 | 0.360 |
Why?
|
Scalp | 2 | 2023 | 388 | 0.340 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2014 | 540 | 0.340 |
Why?
|
Pyoderma Gangrenosum | 1 | 2010 | 85 | 0.320 |
Why?
|
Ultraviolet Rays | 1 | 2014 | 1099 | 0.310 |
Why?
|
Pathology, Clinical | 1 | 2012 | 374 | 0.300 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2012 | 328 | 0.300 |
Why?
|
Exocytosis | 3 | 2008 | 323 | 0.290 |
Why?
|
Mutation | 2 | 2024 | 30188 | 0.250 |
Why?
|
Eczema | 2 | 2018 | 246 | 0.250 |
Why?
|
Vaccination | 1 | 2018 | 3425 | 0.250 |
Why?
|
Anti-Bacterial Agents | 1 | 2023 | 7476 | 0.230 |
Why?
|
Cafe-au-Lait Spots | 1 | 2024 | 20 | 0.230 |
Why?
|
Magnetic Resonance Imaging | 5 | 2024 | 36542 | 0.230 |
Why?
|
Retrospective Studies | 17 | 2024 | 81505 | 0.230 |
Why?
|
Female | 37 | 2024 | 396050 | 0.230 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2024 | 2053 | 0.220 |
Why?
|
Hospitalization | 1 | 2024 | 10803 | 0.220 |
Why?
|
Male | 33 | 2024 | 363740 | 0.220 |
Why?
|
Immunohistochemistry | 5 | 2024 | 11033 | 0.210 |
Why?
|
Azetidines | 1 | 2024 | 150 | 0.210 |
Why?
|
Adrenal Cortex Hormones | 2 | 2018 | 1881 | 0.200 |
Why?
|
Trientine | 1 | 2020 | 12 | 0.180 |
Why?
|
Pamphlets | 1 | 2020 | 71 | 0.180 |
Why?
|
Young Adult | 11 | 2024 | 59849 | 0.170 |
Why?
|
Immunoglobulin G | 1 | 2012 | 4526 | 0.170 |
Why?
|
Glucocorticoids | 2 | 2021 | 2132 | 0.170 |
Why?
|
Melanins | 1 | 2022 | 291 | 0.170 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2021 | 148 | 0.170 |
Why?
|
Genomics | 2 | 2022 | 5926 | 0.170 |
Why?
|
Aminoquinolines | 1 | 2020 | 102 | 0.170 |
Why?
|
Immunologic Factors | 2 | 2022 | 1584 | 0.170 |
Why?
|
Lip | 1 | 2021 | 195 | 0.170 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2020 | 4046 | 0.150 |
Why?
|
Ambulatory Care Facilities | 2 | 2021 | 937 | 0.150 |
Why?
|
Communication Barriers | 1 | 2021 | 418 | 0.150 |
Why?
|
Hospital Costs | 1 | 2024 | 957 | 0.150 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 2008 | 179 | 0.140 |
Why?
|
Patch Tests | 1 | 2018 | 57 | 0.140 |
Why?
|
Remote Consultation | 1 | 2020 | 240 | 0.140 |
Why?
|
Sunlight | 1 | 2019 | 335 | 0.140 |
Why?
|
Histamine Antagonists | 1 | 2018 | 93 | 0.140 |
Why?
|
Age of Onset | 1 | 2024 | 3341 | 0.140 |
Why?
|
Urination | 1 | 2008 | 204 | 0.140 |
Why?
|
Adult | 15 | 2024 | 223055 | 0.140 |
Why?
|
rab GTP-Binding Proteins | 1 | 2008 | 245 | 0.140 |
Why?
|
Comparative Genomic Hybridization | 1 | 2018 | 474 | 0.130 |
Why?
|
Antibodies, Monoclonal | 2 | 2012 | 9241 | 0.130 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6545 | 0.130 |
Why?
|
Down Syndrome | 1 | 2024 | 915 | 0.130 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2019 | 5753 | 0.130 |
Why?
|
Acneiform Eruptions | 1 | 2014 | 4 | 0.120 |
Why?
|
Dermatitis, Phototoxic | 1 | 2014 | 17 | 0.120 |
Why?
|
Health Services Accessibility | 3 | 2022 | 5508 | 0.120 |
Why?
|
Neurons, Afferent | 1 | 2007 | 496 | 0.120 |
Why?
|
Parents | 2 | 2019 | 3590 | 0.120 |
Why?
|
Fluorouracil | 1 | 2020 | 1647 | 0.120 |
Why?
|
Biopsy, Needle | 2 | 2017 | 1614 | 0.120 |
Why?
|
Mohs Surgery | 1 | 2017 | 217 | 0.110 |
Why?
|
Receptors, Purinergic P2 | 1 | 2005 | 149 | 0.110 |
Why?
|
Hyperalgesia | 1 | 2008 | 511 | 0.110 |
Why?
|
Photography | 1 | 2017 | 535 | 0.110 |
Why?
|
Antifungal Agents | 2 | 2019 | 769 | 0.110 |
Why?
|
Urothelium | 1 | 2005 | 275 | 0.110 |
Why?
|
Prognosis | 4 | 2023 | 29915 | 0.110 |
Why?
|
Interferons | 1 | 2017 | 714 | 0.110 |
Why?
|
Physostigmine | 1 | 2002 | 51 | 0.100 |
Why?
|
Estrous Cycle | 1 | 2002 | 62 | 0.100 |
Why?
|
Leg | 1 | 2018 | 1108 | 0.100 |
Why?
|
Boston | 2 | 2023 | 9336 | 0.100 |
Why?
|
Patient Care Planning | 1 | 2018 | 903 | 0.100 |
Why?
|
Administration, Topical | 2 | 2014 | 703 | 0.100 |
Why?
|
Laminin | 1 | 2014 | 404 | 0.100 |
Why?
|
Pemphigoid, Bullous | 1 | 2014 | 108 | 0.100 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2013 | 201 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2018 | 2511 | 0.100 |
Why?
|
Mycophenolic Acid | 1 | 2014 | 346 | 0.090 |
Why?
|
Infant, Newborn | 4 | 2024 | 26337 | 0.090 |
Why?
|
Lower Extremity | 2 | 2017 | 1226 | 0.090 |
Why?
|
Neoplasm Invasiveness | 2 | 2017 | 3597 | 0.090 |
Why?
|
Comorbidity | 2 | 2024 | 10570 | 0.090 |
Why?
|
Documentation | 1 | 2018 | 915 | 0.090 |
Why?
|
Cholinesterase Inhibitors | 1 | 2002 | 241 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3539 | 0.090 |
Why?
|
Rheumatoid Nodule | 1 | 2010 | 15 | 0.090 |
Why?
|
Survival Rate | 3 | 2024 | 12821 | 0.090 |
Why?
|
Measles | 1 | 2012 | 180 | 0.090 |
Why?
|
Necrobiosis Lipoidica | 1 | 2010 | 14 | 0.090 |
Why?
|
Xanthomatosis | 1 | 2010 | 32 | 0.080 |
Why?
|
Alopecia | 2 | 2018 | 415 | 0.080 |
Why?
|
Caregivers | 1 | 2022 | 2304 | 0.080 |
Why?
|
Risk Factors | 8 | 2023 | 74853 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2780 | 0.080 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2012 | 591 | 0.080 |
Why?
|
Cell Membrane | 2 | 2007 | 3633 | 0.080 |
Why?
|
Age Factors | 4 | 2020 | 18380 | 0.080 |
Why?
|
Cohort Studies | 5 | 2024 | 41643 | 0.080 |
Why?
|
Patient Compliance | 1 | 2019 | 2693 | 0.080 |
Why?
|
Monitoring, Physiologic | 1 | 2017 | 1794 | 0.080 |
Why?
|
Pituitary-Adrenal System | 1 | 2002 | 552 | 0.080 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2014 | 666 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20680 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1056 | 0.080 |
Why?
|
Adenosine Triphosphate | 1 | 2005 | 1999 | 0.080 |
Why?
|
Patient Care Team | 2 | 2019 | 2513 | 0.080 |
Why?
|
Survivors | 1 | 2019 | 2373 | 0.080 |
Why?
|
Curriculum | 1 | 2022 | 3780 | 0.080 |
Why?
|
Referral and Consultation | 3 | 2021 | 3614 | 0.080 |
Why?
|
Reference Standards | 1 | 2012 | 1013 | 0.080 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2002 | 701 | 0.080 |
Why?
|
Lichen Planus | 1 | 2009 | 70 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2019 | 9372 | 0.070 |
Why?
|
Sjogren's Syndrome | 1 | 2010 | 240 | 0.070 |
Why?
|
Lung Neoplasms | 1 | 2013 | 13446 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2013 | 1834 | 0.070 |
Why?
|
Dermatitis | 1 | 2010 | 200 | 0.070 |
Why?
|
Health Behavior | 1 | 2019 | 2649 | 0.070 |
Why?
|
Postoperative Complications | 1 | 2010 | 15794 | 0.070 |
Why?
|
Physicians | 2 | 2023 | 4587 | 0.070 |
Why?
|
United States | 7 | 2024 | 72896 | 0.070 |
Why?
|
Interleukins | 1 | 2012 | 791 | 0.070 |
Why?
|
Massachusetts | 1 | 2020 | 8875 | 0.070 |
Why?
|
Eosinophils | 1 | 2012 | 945 | 0.070 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2014 | 1084 | 0.070 |
Why?
|
Paraproteinemias | 1 | 2010 | 251 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8529 | 0.070 |
Why?
|
Lipomatosis | 1 | 2007 | 112 | 0.070 |
Why?
|
Biological Specimen Banks | 1 | 2012 | 787 | 0.070 |
Why?
|
Appointments and Schedules | 2 | 2020 | 441 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1409 | 0.070 |
Why?
|
Intestine, Small | 1 | 2012 | 1216 | 0.060 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4110 | 0.060 |
Why?
|
Hair | 1 | 2009 | 508 | 0.060 |
Why?
|
Immunosuppressive Agents | 2 | 2019 | 4207 | 0.060 |
Why?
|
Autoantibodies | 1 | 2014 | 2112 | 0.060 |
Why?
|
Neoplasm Staging | 2 | 2017 | 11205 | 0.060 |
Why?
|
Genetic Testing | 1 | 2018 | 3590 | 0.060 |
Why?
|
Diagnostic Errors | 1 | 2012 | 1276 | 0.060 |
Why?
|
Bone Marrow Transplantation | 1 | 2012 | 2729 | 0.060 |
Why?
|
Incidence | 2 | 2020 | 21501 | 0.060 |
Why?
|
Sarcoidosis | 1 | 2010 | 534 | 0.060 |
Why?
|
Cross-Sectional Studies | 6 | 2022 | 26276 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 4056 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2019 | 10428 | 0.050 |
Why?
|
Immunotherapy | 1 | 2019 | 4752 | 0.050 |
Why?
|
Methotrexate | 1 | 2010 | 1720 | 0.050 |
Why?
|
Early Detection of Cancer | 3 | 2022 | 3237 | 0.050 |
Why?
|
Skin Pigmentation | 1 | 2024 | 277 | 0.050 |
Why?
|
Staphylococcus aureus | 1 | 2010 | 1424 | 0.050 |
Why?
|
Risk Assessment | 3 | 2023 | 24278 | 0.050 |
Why?
|
Hypertrichosis | 1 | 2021 | 31 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39226 | 0.050 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2024 | 295 | 0.050 |
Why?
|
Skin Care | 1 | 2021 | 54 | 0.050 |
Why?
|
Hair Removal | 1 | 2021 | 41 | 0.050 |
Why?
|
Middle Aged | 8 | 2024 | 223016 | 0.050 |
Why?
|
Antineoplastic Agents | 3 | 2019 | 13635 | 0.050 |
Why?
|
Purines | 1 | 2024 | 615 | 0.040 |
Why?
|
Antirheumatic Agents | 1 | 2010 | 1362 | 0.040 |
Why?
|
Electronics | 1 | 2021 | 314 | 0.040 |
Why?
|
Rabbits | 2 | 2007 | 4731 | 0.040 |
Why?
|
Graft vs Host Disease | 1 | 2012 | 3079 | 0.040 |
Why?
|
Stem Cells | 1 | 2012 | 3539 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2007 | 1899 | 0.040 |
Why?
|
Canada | 1 | 2024 | 2119 | 0.040 |
Why?
|
International Classification of Diseases | 1 | 2024 | 933 | 0.040 |
Why?
|
Cytoplasmic Vesicles | 1 | 2008 | 72 | 0.040 |
Why?
|
Treatment Outcome | 3 | 2024 | 65223 | 0.040 |
Why?
|
Neoplasm Transplantation | 1 | 2022 | 2011 | 0.040 |
Why?
|
Pruritus | 1 | 2021 | 377 | 0.040 |
Why?
|
Primary Health Care | 3 | 2020 | 4735 | 0.040 |
Why?
|
Reflex, Abnormal | 1 | 2008 | 83 | 0.040 |
Why?
|
Emollients | 1 | 2018 | 41 | 0.040 |
Why?
|
Cystitis | 1 | 2008 | 96 | 0.040 |
Why?
|
Baths | 1 | 2018 | 52 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2013 | 5335 | 0.040 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2010 | 2152 | 0.040 |
Why?
|
Cell Shape | 1 | 2008 | 372 | 0.040 |
Why?
|
Crohn Disease | 1 | 2010 | 2283 | 0.030 |
Why?
|
Neutrophils | 1 | 2010 | 3770 | 0.030 |
Why?
|
Vitiligo | 1 | 2018 | 96 | 0.030 |
Why?
|
Iatrogenic Disease | 1 | 2020 | 552 | 0.030 |
Why?
|
Transforming Growth Factor alpha | 1 | 2007 | 134 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8601 | 0.030 |
Why?
|
Cycloheximide | 1 | 2007 | 339 | 0.030 |
Why?
|
Mutant Proteins | 1 | 2008 | 485 | 0.030 |
Why?
|
Quality of Life | 1 | 2018 | 13466 | 0.030 |
Why?
|
Nurse Practitioners | 1 | 2019 | 270 | 0.030 |
Why?
|
Phenotype | 1 | 2014 | 16706 | 0.030 |
Why?
|
Disease Management | 2 | 2018 | 2532 | 0.030 |
Why?
|
Patients | 1 | 2023 | 909 | 0.030 |
Why?
|
Administration, Oral | 1 | 2024 | 4018 | 0.030 |
Why?
|
Capital Financing | 1 | 2016 | 58 | 0.030 |
Why?
|
Office Visits | 1 | 2020 | 594 | 0.030 |
Why?
|
Electric Capacitance | 1 | 2005 | 11 | 0.030 |
Why?
|
Mice, Knockout | 3 | 2012 | 14445 | 0.030 |
Why?
|
Receptors, Purinergic P2X2 | 1 | 2005 | 8 | 0.030 |
Why?
|
Receptors, Purinergic P2X3 | 1 | 2005 | 9 | 0.030 |
Why?
|
Purinergic P2 Receptor Agonists | 1 | 2005 | 13 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2008 | 898 | 0.030 |
Why?
|
Physical Examination | 1 | 2021 | 1263 | 0.030 |
Why?
|
Pyridoxal Phosphate | 1 | 2005 | 123 | 0.030 |
Why?
|
Brain | 1 | 2022 | 27178 | 0.030 |
Why?
|
Waiting Lists | 1 | 2020 | 778 | 0.030 |
Why?
|
Receptor, erbB-2 | 2 | 2014 | 2592 | 0.030 |
Why?
|
Benzoyl Peroxide | 1 | 2014 | 22 | 0.030 |
Why?
|
Sulfonamides | 1 | 2024 | 1981 | 0.030 |
Why?
|
Cost of Illness | 1 | 2024 | 1949 | 0.030 |
Why?
|
Research | 1 | 2023 | 1974 | 0.030 |
Why?
|
Clindamycin | 1 | 2014 | 138 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 2007 | 698 | 0.030 |
Why?
|
Population Surveillance | 1 | 2024 | 2595 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2012 | 20131 | 0.030 |
Why?
|
Pyrazoles | 1 | 2024 | 2031 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 2 | 2007 | 8105 | 0.030 |
Why?
|
Needs Assessment | 1 | 2019 | 1139 | 0.030 |
Why?
|
Human Growth Hormone | 1 | 2008 | 639 | 0.030 |
Why?
|
Time Factors | 2 | 2018 | 40109 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2014 | 59506 | 0.030 |
Why?
|
Aftercare | 1 | 2019 | 914 | 0.030 |
Why?
|
Mucous Membrane | 1 | 2007 | 656 | 0.030 |
Why?
|
Mice | 5 | 2022 | 81788 | 0.030 |
Why?
|
Minocycline | 1 | 2014 | 168 | 0.030 |
Why?
|
Outpatients | 1 | 2021 | 1591 | 0.030 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 484 | 0.030 |
Why?
|
Apyrase | 1 | 2005 | 373 | 0.030 |
Why?
|
Epithelium | 1 | 2007 | 1602 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2022 | 2423 | 0.030 |
Why?
|
Arginine Vasopressin | 1 | 2002 | 125 | 0.030 |
Why?
|
Sensory Receptor Cells | 1 | 2007 | 510 | 0.030 |
Why?
|
Sampling Studies | 1 | 2014 | 610 | 0.030 |
Why?
|
Tyrosine | 1 | 2007 | 1427 | 0.030 |
Why?
|
Oximes | 1 | 2014 | 305 | 0.020 |
Why?
|
Motivation | 1 | 2022 | 2018 | 0.020 |
Why?
|
Mice, Inbred C57BL | 3 | 2012 | 22323 | 0.020 |
Why?
|
Radiotherapy | 1 | 2019 | 1493 | 0.020 |
Why?
|
Pyrimidines | 1 | 2024 | 3047 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2007 | 1240 | 0.020 |
Why?
|
Corticosterone | 1 | 2002 | 301 | 0.020 |
Why?
|
Health Services Needs and Demand | 1 | 2019 | 1405 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 2014 | 715 | 0.020 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2013 | 303 | 0.020 |
Why?
|
Cell Line, Transformed | 1 | 2013 | 858 | 0.020 |
Why?
|
Mycoses | 1 | 2014 | 389 | 0.020 |
Why?
|
Pyrimidinones | 1 | 2014 | 384 | 0.020 |
Why?
|
Receptors, Interleukin | 1 | 2012 | 243 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2010 | 5889 | 0.020 |
Why?
|
Aged | 4 | 2024 | 171178 | 0.020 |
Why?
|
Endocytosis | 1 | 2005 | 951 | 0.020 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2013 | 257 | 0.020 |
Why?
|
Interleukin-23 | 1 | 2012 | 202 | 0.020 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2002 | 618 | 0.020 |
Why?
|
Wound Healing | 1 | 2021 | 2792 | 0.020 |
Why?
|
Animals | 6 | 2022 | 168730 | 0.020 |
Why?
|
Psoriasis | 1 | 2018 | 919 | 0.020 |
Why?
|
Public Health | 1 | 2023 | 2678 | 0.020 |
Why?
|
Vaginal Smears | 1 | 2002 | 506 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2007 | 1657 | 0.020 |
Why?
|
Autoantigens | 1 | 2014 | 883 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2022 | 4521 | 0.020 |
Why?
|
Melanocytes | 1 | 2013 | 504 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2014 | 866 | 0.020 |
Why?
|
Glycoproteins | 1 | 2007 | 2195 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2331 | 0.020 |
Why?
|
Signal Transduction | 3 | 2007 | 23588 | 0.020 |
Why?
|
Rats | 2 | 2007 | 23707 | 0.020 |
Why?
|
Pyridones | 1 | 2014 | 816 | 0.020 |
Why?
|
Causality | 1 | 2014 | 1247 | 0.020 |
Why?
|
Gene Amplification | 1 | 2013 | 1089 | 0.020 |
Why?
|
Imidazoles | 1 | 2014 | 1164 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2020 | 18064 | 0.020 |
Why?
|
Pain Measurement | 1 | 2008 | 3559 | 0.020 |
Why?
|
Drug Combinations | 1 | 2014 | 2074 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2014 | 21064 | 0.020 |
Why?
|
Health Care Reform | 1 | 2016 | 1258 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 3229 | 0.020 |
Why?
|
Phosphorylation | 1 | 2007 | 8278 | 0.020 |
Why?
|
Cystic Fibrosis | 1 | 2014 | 1287 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2007 | 3682 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2012 | 6219 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5529 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 2839 | 0.010 |
Why?
|
Pediatrics | 1 | 2018 | 3602 | 0.010 |
Why?
|
Quality Improvement | 1 | 2018 | 3845 | 0.010 |
Why?
|
Health Personnel | 1 | 2016 | 3386 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2014 | 2822 | 0.010 |
Why?
|
Calcium | 1 | 2005 | 5767 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2012 | 5879 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 22227 | 0.010 |
Why?
|
Neoplasms | 1 | 2010 | 22349 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8698 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15881 | 0.010 |
Why?
|
Sex Factors | 1 | 2002 | 10607 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5368 | 0.010 |
Why?
|
Apoptosis | 1 | 2013 | 9512 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13613 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 17063 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2012 | 18289 | 0.010 |
Why?
|
HIV Infections | 1 | 2007 | 17530 | 0.000 |
Why?
|